Forte Biosciences (FBRX) Non-Current Assets (2016 - 2026)
Forte Biosciences (FBRX) reported Non-Current Assets of $2.1 million for Q1 2026, up 601.99% year-over-year from $301000.0 in Q1 2025, and down 3.52% quarter-over-quarter from $2.2 million in Q4 2025.
Forte Biosciences (FBRX) Non-Current Assets (2016 - 2026) Analysis & Trends
Forte Biosciences (FBRX) has 11 years of Non-Current Assets data on file, last reported at $2.1 million in Q1 2026.
- Non-Current Assets for Q1 2026 came in at $2.1 million, up 601.99% year-over-year; the trailing twelve-month figure through Mar 2026 was $6.1 million (up 429.46% YoY), and the FY2025 annual result was $2.2 million, up 918.6% from the prior year.
- Non-Current Assets slipped to $2.1 million in Q1 2026 per FBRX's latest filing, from $2.2 million in the prior quarter.
- Over five years, Non-Current Assets peaked at $2.2 million in Q4 2025 and troughed at $167000.0 in Q2 2025.
- A 5-year average of $759647.1 and a median of $515000.0 in 2024 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2024 and 2025: Non-Current Assets slumped 67.08% in 2024, then soared 918.6% in 2025.
- A 5-year view of Non-Current Assets shows it stood at $486000.0 in 2022, then soared by 34.36% to $653000.0 in 2023, then tumbled by 67.08% to $215000.0 in 2024, then soared by 918.6% to $2.2 million in 2025, then decreased by 3.52% to $2.1 million in 2026.
- Business Quant data shows FBRX's Non-Current Assets at $2.1 million in Q1 2026, $2.2 million in Q4 2025, and $1.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 62,953.78 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 289.41 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 4.56 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 486.60 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 30.30 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 5.18 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 14.75 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 39.71 Mn |
| 10 | Forte Biosciences | 70.77 Mn | 12.55 Mn | - | 2.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.11 Mn |
| Dec 31, 2025 | 2.19 Mn |
| Sep 30, 2025 | 1.68 Mn |
| Jun 30, 2025 | 167,000.00 |
| Mar 31, 2025 | 301,000.00 |
| Dec 31, 2024 | 215,000.00 |
| Sep 30, 2024 | 278,000.00 |
| Jun 30, 2024 | 367,000.00 |
| Mar 31, 2024 | 515,000.00 |
| Dec 31, 2023 | 653,000.00 |
| Sep 30, 2023 | 777,000.00 |
| Jun 30, 2023 | 437,000.00 |
| Mar 31, 2023 | 437,000.00 |
| Dec 31, 2022 | 486,000.00 |
| Sep 30, 2022 | 534,000.00 |
| Jun 30, 2022 | 874,000.00 |
| Mar 31, 2022 | 893,000.00 |
| Dec 31, 2021 | 786,000.00 |
| Sep 30, 2021 | 834,000.00 |
| Jun 30, 2021 | 1.01 Mn |